Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01662492 · ClinicalTrials.gov registry record · Phase 3
A Study Using Botulinum Toxin Type A as Headache Prophylaxis in Adolescents With Chronic Migraine
A Phase 3 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 3
- Development phase
- 125
- Enrollment target
NCT01662492: Completed Phase 3 study, sponsored by Allergan.
NCT01662492 is a Phase 3 study that has completed, run by Allergan. The registered enrollment target is 125 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (84% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01662492, a Phase 3 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 125 participants
- Enrollment target
Study Summary
To evaluate the efficacy and safety of Botulinum Toxin Type A versus placebo (normal saline) as headache prophylaxis in adolescents (children 12 to 17) with chronic migraine.
Primary Outcome
Change from baseline in the frequency of headache days during the 28-day period, ending with Week 12 in the Intent-to-Treat population. A headache day for a patient is defined as a calendar day with 1 or more total hours of headache as recorded by the patient in the electronic diary.
Interventions
- DRUG Placebo (Normal Saline)
- BIOLOGICAL Botulinum toxin type A Dose 1
- BIOLOGICAL Botulinum toxin type A Dose 2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2012-10 |
| Est. Completion | 2016-08 |
| Phase | Phase 3 |
What the finished NCT01662492 record still lists
NCT01662492 is an interventional study that assigns participants to a tested intervention. The registered 125 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (84% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo (Normal Saline) is the first listed.
NCT01662492 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01662492 about?
NCT01662492 is a clinical study titled "A Study Using Botulinum Toxin Type A as Headache Prophylaxis in Adolescents With Chronic Migraine". To evaluate the efficacy and safety of Botulinum Toxin Type A versus placebo (normal saline) as headache prophylaxis in adolescents (children 12 to 17) with chronic migraine.
What is the current status of trial NCT01662492?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 125 participants. The study started on 2012-10. Estimated completion is 2016-08.
What interventions are being tested in trial NCT01662492?
The interventions under investigation include: Placebo (Normal Saline) (DRUG), Botulinum toxin type A Dose 1 (BIOLOGICAL), Botulinum toxin type A Dose 2 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01662492?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01662492's enrollment target sits among peer trials
125 1605th of 2000 higher than 391 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02717039 · 125 participants
Pharmacogenomics of Heparin-Induced Thrombocytopenia
- NCT02763033 · 125 participants · Phase 2
Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients
- NCT02793999 · 125 participants
Perinatal Brain Injury: Potential of Innovative NIRS to Optimize Hypothermia
- NCT03003299 · 125 participants · NA
PARTNER 3 Trial - Aortic Valve-in-Valve
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia